ARGUMENTS FOR A CHANGE IN PRACTICE - Single antiplatelet therapy in combination with reduced oral anticoagulation reduces the rate of bleeding events in comparison to triple therapy after PCI in patients with atrial fibrillation (PIONEER AF-PCI, WOEST). ARGUMENTS AGAINST A CHANGE IN PRACTICE - Current trials are underpowered to assess the risk of ischaemic events adequately, especially stent thrombosis. - Differences in bleeding events are mainly driven by minor bleedings. - Patients must be responders to the agent used in case of single antiplatelet therapy in combination with oral anticoagulation. Results of further ongoing trials (REDUAL-PCI, ENTRUSTAF-PCI, AUGUSTUS) are expected soon.
|Publication status||Published - Aug 1 2017|
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine